Lloyd T. Lam
AbbVie (United States)(US)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, CAR-T cell therapy research, Chromatin Remodeling and Cancer, RNA Interference and Gene Delivery
Most-Cited Works
- → ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets(2013)2,976 cited
- → Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways(2008)974 cited
- → Molecular Diagnosis of Burkitt's Lymphoma(2006)903 cited
- → Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma(2008)872 cited
- → Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours(2017)825 cited
- → A loss-of-function RNA interference screen for molecular targets in cancer(2006)605 cited
- → Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer(2020)393 cited
- → Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol(2001)372 cited
- → Ribosomal Protein S3: A KH Domain Subunit in NF-κB Complexes that Mediates Selective Gene Regulation(2007)354 cited
- → Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma(2007)351 cited